Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden
Authors:
- 6 June 2017
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 96 (8) , 1297-1302
Abstract
The most common causes of morbidity and mortality in myeloproliferative neoplasms (MPN) are thrombotic and hemorrhagic complications. The JAK2V617F mutation, commonly found in MPN, correlates with several clinical and laboratory characteristics even if the relevance of JAK2V617F allele burden in the natural history of these diseases is unclear. In this study we searched, a relation between thrombotic and hemorrhagic complications and JAK2V617F allele burden level in MPN patients. We evaluated 253 consecutive MPN [121 essential thrombocythemia (ET), 124 polycythemia vera (PV), and 8 primary myelofibrosis (PMF)] patients in whom the JAK2V617F allele burden was available, all studied and followed (median 8.8 years) in our department. Patients were stratified accordingly to their JAK2V617F allele burden, into four quartiles (1st 75%). Significantly higher incidence of thromboses (p = 0.001) and hemorrhages (p < 0.001) during follow-up has been observed in higher quartiles when compared to lower ones. Thrombosis- and hemorrhage-free survivals were poorer in patients belonging to the highest quartile. Our data suggest that MPN patients with JAK2V617F allele burden higher than 75% have to be considered as high risk patients, being prone to develop thrombo-hemorrhagic complications during the disease course.Keywords
This publication has 29 references indexed in Scilit:
- Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteriaLeukemia, 2011
- Thrombohemorrhagic complications of myeloproliferative disordersBlood Reviews, 2010
- Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemiaBlood, 2010
- Advances in Understanding and Management of Myeloproliferative NeoplasmsCA: A Cancer Journal for Clinicians, 2009
- Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatmentsHaematologica, 2008
- JAK2V617F mutation in essential thrombocythaemia: clinical associations and long‐term prognostic relevanceBritish Journal of Haematology, 2005
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersNew England Journal of Medicine, 2005
- Vascular and Neoplastic Risk in a Large Cohort of Patients With Polycythemia VeraJournal of Clinical Oncology, 2005
- Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersThe Lancet, 2005
- Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disordersAnnals of Hematology, 1991